title: [Research progress regarding the clinical evaluation on recombinant human papillomavirus vaccines].
abstract: Human papillomavirus (HPV) is the main cause for cervical cancer, anogenital cancers and genital warts. Three HPV vaccines have been licensed abroad. Data from clinical trials showed high efficacy of the HPV vaccines in young women with 90%-100% vaccine-related HPV diseases prevented. Though efficacy of the vaccine appears lower in older women, this population can still benefit from vaccination. Immunobriging trials show that the two-dose schedule in 9-14 years old girls elicits non-inferior immune response than the three-dose one in young adults. In addition, HPV vaccines can reduce the recurrent rates in CIN2+ patients after therapeutic surgery and the vaccines have cross-protection aganist diseases caused by non-vaccine type HPV. Safety data on HPV vaccines are assuring. Thus HPV vaccine should be widely used in adolescent girls and women of appropriate age groups.
authors.affiliation: The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xia Men 361102, China.
authors.forename: W G
authors.initials: WG
authors.lastname: He
authors.forename: J
authors.initials: J
authors.lastname: Zhao
authors.forename: S J
authors.initials: SJ
authors.lastname: Huang
authors.forename: T
authors.initials: T
authors.lastname: Wu
mesh_terms: D003218:Condylomata Acuminata; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms; D014611:Vaccination
chemical_list: D053918:Papillomavirus Vaccines